MAP2K7 and juvenile myelomonocytic leukemia: SCS datasets also identified therapeutically relevant information in JMML hematopoietic stem/progenitor cells (HSPCs), where reduced clonogenicity and induced apoptosis was observed after glucose transporter 1 (GLUT1) inhibitor treatment, which seemed to be synergistic with mitogen-activated extracellular signal-regulated kinase (MEK) inhibition [37].